Inhibition of phosphodiesterase 4 and 7 regulates breast cancer cell proliferation

cAMP regulates key processes in mammary cell biology. Previous studies suggested reduced cAMP production in more malignant cells. This study investigates the role of cAMP in mammary biology using non-tumor (MCF-10A and HBL-100) and tumor (MCF-7 and MDA-MB-231) human breast cell lines. cAMP levels w...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Biochimica et biophysica acta. General subjects Ročník 1869; číslo 11; s. 130850
Hlavní autoři:	Mayora Justel, Carla, Valladares, Tamara, Gargiulo, Lucía, González-Pardo, Verónica, De Sousa, Maximiliano, Esandi, María del Carmen, Davio, Carlos, Lüthy, Isabel, Bruzzone, Ariana
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier B.V 01.10.2025
Témata:	1-Methyl-3-isobutylxanthine - pharmacology Aminopyridines - pharmacology Benzamides - pharmacology Breast neoplasm Breast Neoplasms - drug therapy Breast Neoplasms - enzymology Breast Neoplasms - metabolism Breast Neoplasms - pathology Cell line Cell Line, Tumor Cell Movement - drug effects Cell Proliferation - drug effects Cell Survival - drug effects Cyclic AMP Cyclic AMP - metabolism Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism Cyclic Nucleotide Phosphodiesterases, Type 7 - antagonists & inhibitors Cyclic Nucleotide Phosphodiesterases, Type 7 - metabolism Cyclopropanes - pharmacology Female Gene expression Gene Expression Regulation, Neoplastic - drug effects Humans MCF-7 Cells Phosphodiesterase 4 inhibitor Phosphodiesterase 4 Inhibitors - pharmacology Phosphodiesterase Inhibitors - pharmacology Roflumilast Cyclic AMP Cell line Roflumilast Phosphodiesterase 4 inhibitor Gene expression Breast neoplasm
ISSN:	0304-4165, 1872-8006, 1872-8006
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	cAMP regulates key processes in mammary cell biology. Previous studies suggested reduced cAMP production in more malignant cells. This study investigates the role of cAMP in mammary biology using non-tumor (MCF-10A and HBL-100) and tumor (MCF-7 and MDA-MB-231) human breast cell lines. cAMP levels were quantified using a competitive radio-binding assay. Cell proliferation and viability were assessed by cell counting and MTT assay. Gene expression was analyzed by real-time PCR and immunofluorescence. Additional assays included migration, colony formation, annexin V/IP staining, comet assay, and caspase-3 activity. Public datasets were consulted. Phosphodiesterase (PDE) inhibitors were tested: the broad-spectrum PDE inhibitor IBMX (3-Isobutyl-1-methylxanthine), the PDE4-selective inhibitor roflumilast, and the PDE7-selective inhibitor BRL-50481. Non-tumor cells produced more cAMP than tumor cells, with or without IBMX. IBMX decreases cell proliferation and viability in all cell lines. Gene expression data revealed higher ADCY2, 3, 4, 5, 6, and 8 expression in normal tissues. Roflumilast reduced cell viability in all tested cells, while the PDE7-specific inhibitor BRL-50481 only affected MCF-7 cells. All PDE inhibitors exhibited an additive effect with tamoxifen, reducing MCF-7 cell viability. In tumor cells roflumilast decreased cell migration. In MDA-MB-231 cells, although IBMX and roflumilast showed a trend toward further decreasing viability compared to doxorubicin or paclitaxel alone, the differences were not statistically significant. The selective PDE4 inhibitor roflumilast demonstrated potential as a therapeutic agent when combined with specific breast cancer treatments, offering a novel approach in breast cancer therapy. •cAMP levels are higher in non-tumor breast cells compared to breast cancer cells.•ADCY gene expression is lower in tumor tissues compared to normal tissues.•PDE4D expression is elevated in MDA-MB-231 breast cancer cells.•Roflumilast reduces migration and cell viability in breast cancer cell lines.•PDE inhibitors enhance tamoxifen effects in MCF-7 breast cancer cells.
AbstractList	cAMP regulates key processes in mammary cell biology. Previous studies suggested reduced cAMP production in more malignant cells. This study investigates the role of cAMP in mammary biology using non-tumor (MCF-10 A and HBL-100) and tumor (MCF-7 and MDA-MB-231) human breast cell lines.PURPOSEcAMP regulates key processes in mammary cell biology. Previous studies suggested reduced cAMP production in more malignant cells. This study investigates the role of cAMP in mammary biology using non-tumor (MCF-10 A and HBL-100) and tumor (MCF-7 and MDA-MB-231) human breast cell lines.cAMP levels were quantified using a competitive radio-binding assay. Cell proliferation and viability were assessed by cell counting and MTT assay. Gene expression was analyzed by real-time PCR and immunofluorescence. Additional assays included migration, colony formation, annexin V/IP staining, comet assay, and caspase-3 activity. Public datasets were consulted. Phosphodiesterase (PDE) inhibitors were tested: the broad-spectrum PDE inhibitor IBMX (3-Isobutyl-1-methylxanthine), the PDE4-selective inhibitor roflumilast, and the PDE7-selective inhibitor BRL-50481.METHODScAMP levels were quantified using a competitive radio-binding assay. Cell proliferation and viability were assessed by cell counting and MTT assay. Gene expression was analyzed by real-time PCR and immunofluorescence. Additional assays included migration, colony formation, annexin V/IP staining, comet assay, and caspase-3 activity. Public datasets were consulted. Phosphodiesterase (PDE) inhibitors were tested: the broad-spectrum PDE inhibitor IBMX (3-Isobutyl-1-methylxanthine), the PDE4-selective inhibitor roflumilast, and the PDE7-selective inhibitor BRL-50481.Non-tumor cells produced more cAMP than tumor cells, with or without IBMX. IBMX decreases cell proliferation and viability in all cell lines. Gene expression data revealed higher ADCY2, 3, 4, 5, 6, and 8 expression in normal tissues. Roflumilast reduced cell viability in all tested cells, while the PDE7-specific inhibitor BRL-50481 only affected MCF-7 cells. All PDE inhibitors exhibited an additive effect with tamoxifen, reducing MCF-7 cell viability. In tumor cells roflumilast decreased cell migration. In MDA-MB-231 cells, although IBMX and roflumilast showed a trend toward further decreasing viability compared to doxorubicin or paclitaxel alone, the differences were not statistically significant.RESULTSNon-tumor cells produced more cAMP than tumor cells, with or without IBMX. IBMX decreases cell proliferation and viability in all cell lines. Gene expression data revealed higher ADCY2, 3, 4, 5, 6, and 8 expression in normal tissues. Roflumilast reduced cell viability in all tested cells, while the PDE7-specific inhibitor BRL-50481 only affected MCF-7 cells. All PDE inhibitors exhibited an additive effect with tamoxifen, reducing MCF-7 cell viability. In tumor cells roflumilast decreased cell migration. In MDA-MB-231 cells, although IBMX and roflumilast showed a trend toward further decreasing viability compared to doxorubicin or paclitaxel alone, the differences were not statistically significant.The selective PDE4 inhibitor roflumilast demonstrated potential as a therapeutic agent when combined with specific breast cancer treatments, offering a novel approach in breast cancer therapy.CONCLUSIONThe selective PDE4 inhibitor roflumilast demonstrated potential as a therapeutic agent when combined with specific breast cancer treatments, offering a novel approach in breast cancer therapy. cAMP regulates key processes in mammary cell biology. Previous studies suggested reduced cAMP production in more malignant cells. This study investigates the role of cAMP in mammary biology using non-tumor (MCF-10A and HBL-100) and tumor (MCF-7 and MDA-MB-231) human breast cell lines. cAMP levels were quantified using a competitive radio-binding assay. Cell proliferation and viability were assessed by cell counting and MTT assay. Gene expression was analyzed by real-time PCR and immunofluorescence. Additional assays included migration, colony formation, annexin V/IP staining, comet assay, and caspase-3 activity. Public datasets were consulted. Phosphodiesterase (PDE) inhibitors were tested: the broad-spectrum PDE inhibitor IBMX (3-Isobutyl-1-methylxanthine), the PDE4-selective inhibitor roflumilast, and the PDE7-selective inhibitor BRL-50481. Non-tumor cells produced more cAMP than tumor cells, with or without IBMX. IBMX decreases cell proliferation and viability in all cell lines. Gene expression data revealed higher ADCY2, 3, 4, 5, 6, and 8 expression in normal tissues. Roflumilast reduced cell viability in all tested cells, while the PDE7-specific inhibitor BRL-50481 only affected MCF-7 cells. All PDE inhibitors exhibited an additive effect with tamoxifen, reducing MCF-7 cell viability. In tumor cells roflumilast decreased cell migration. In MDA-MB-231 cells, although IBMX and roflumilast showed a trend toward further decreasing viability compared to doxorubicin or paclitaxel alone, the differences were not statistically significant. The selective PDE4 inhibitor roflumilast demonstrated potential as a therapeutic agent when combined with specific breast cancer treatments, offering a novel approach in breast cancer therapy. cAMP regulates key processes in mammary cell biology. Previous studies suggested reduced cAMP production in more malignant cells. This study investigates the role of cAMP in mammary biology using non-tumor (MCF-10A and HBL-100) and tumor (MCF-7 and MDA-MB-231) human breast cell lines. cAMP levels were quantified using a competitive radio-binding assay. Cell proliferation and viability were assessed by cell counting and MTT assay. Gene expression was analyzed by real-time PCR and immunofluorescence. Additional assays included migration, colony formation, annexin V/IP staining, comet assay, and caspase-3 activity. Public datasets were consulted. Phosphodiesterase (PDE) inhibitors were tested: the broad-spectrum PDE inhibitor IBMX (3-Isobutyl-1-methylxanthine), the PDE4-selective inhibitor roflumilast, and the PDE7-selective inhibitor BRL-50481. Non-tumor cells produced more cAMP than tumor cells, with or without IBMX. IBMX decreases cell proliferation and viability in all cell lines. Gene expression data revealed higher ADCY2, 3, 4, 5, 6, and 8 expression in normal tissues. Roflumilast reduced cell viability in all tested cells, while the PDE7-specific inhibitor BRL-50481 only affected MCF-7 cells. All PDE inhibitors exhibited an additive effect with tamoxifen, reducing MCF-7 cell viability. In tumor cells roflumilast decreased cell migration. In MDA-MB-231 cells, although IBMX and roflumilast showed a trend toward further decreasing viability compared to doxorubicin or paclitaxel alone, the differences were not statistically significant. The selective PDE4 inhibitor roflumilast demonstrated potential as a therapeutic agent when combined with specific breast cancer treatments, offering a novel approach in breast cancer therapy. •cAMP levels are higher in non-tumor breast cells compared to breast cancer cells.•ADCY gene expression is lower in tumor tissues compared to normal tissues.•PDE4D expression is elevated in MDA-MB-231 breast cancer cells.•Roflumilast reduces migration and cell viability in breast cancer cell lines.•PDE inhibitors enhance tamoxifen effects in MCF-7 breast cancer cells.
ArticleNumber	130850
Author	Davio, Carlos Gargiulo, Lucía González-Pardo, Verónica De Sousa, Maximiliano Lüthy, Isabel Esandi, María del Carmen Bruzzone, Ariana Mayora Justel, Carla Valladares, Tamara
Author_xml	– sequence: 1 givenname: Carla surname: Mayora Justel fullname: Mayora Justel, Carla email: cmayorajustel@inibibb-conicet.gob.ar organization: Instituto de Investigaciones Bioquímicas de Bahía Blanca INIBIBB-UNS-CONICET, Camino la Carrindanga Km 7, 8000 Bahía Blanca, Argentina – sequence: 2 givenname: Tamara surname: Valladares fullname: Valladares, Tamara organization: Instituto de Investigaciones Bioquímicas de Bahía Blanca INIBIBB-UNS-CONICET, Camino la Carrindanga Km 7, 8000 Bahía Blanca, Argentina – sequence: 3 givenname: Lucía surname: Gargiulo fullname: Gargiulo, Lucía organization: Instituto de Biología y Medicina Experimental IBYME-CONICET, Vuelta de Obligado 2490, 1428 Ciudad Autónoma de Buenos Aires, Argentina – sequence: 4 givenname: Verónica surname: González-Pardo fullname: González-Pardo, Verónica email: vgpardo@criba.edu.ar organization: Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, 8000 Bahía Blanca, Argentina – sequence: 5 givenname: Maximiliano surname: De Sousa fullname: De Sousa, Maximiliano organization: Instituto de Investigaciones Farmacológicas ININFA-UBA-CONICET, Junín 456, C1113AAD Ciudad Autónoma de Buenos Aires, Argentina – sequence: 6 givenname: María del Carmen surname: Esandi fullname: Esandi, María del Carmen email: cesandi@criba.edu.ar organization: Instituto de Investigaciones Bioquímicas de Bahía Blanca INIBIBB-UNS-CONICET, Camino la Carrindanga Km 7, 8000 Bahía Blanca, Argentina – sequence: 7 givenname: Carlos surname: Davio fullname: Davio, Carlos organization: Instituto de Investigaciones Farmacológicas ININFA-UBA-CONICET, Junín 456, C1113AAD Ciudad Autónoma de Buenos Aires, Argentina – sequence: 8 givenname: Isabel surname: Lüthy fullname: Lüthy, Isabel email: i.luthy@ibyme.org.ar organization: Instituto de Biología y Medicina Experimental IBYME-CONICET, Vuelta de Obligado 2490, 1428 Ciudad Autónoma de Buenos Aires, Argentina – sequence: 9 givenname: Ariana surname: Bruzzone fullname: Bruzzone, Ariana email: abruzzone@inibibb-conicet.gob.ar organization: Instituto de Investigaciones Bioquímicas de Bahía Blanca INIBIBB-UNS-CONICET, Camino la Carrindanga Km 7, 8000 Bahía Blanca, Argentina
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/40816541$$D View this record in MEDLINE/PubMed
BookMark	eNp9kF1LwzAYhYNM3If-A5FcetOaNEnb3Qgy_BgMBNHrkCZvtoyunUkr-O9N6fTSQAiEc877nmeOJk3bAELXlKSU0Pxun1aV2kKTZiQTKWWkFOQMzWhZZElJSD5BM8IITzjNxRTNQ9iTeMRSXKApJ2X85XSG3tbNzlWuc22DW4uPuzbEaxyEDrwKgDlWjcEF9rDta9VBwJUHFTqsVaPBYw11jY--rZ2NhiHnEp1bVQe4Or0L9PH0-L56STavz-vVwybRjOddUkApjGWWxzZQKFpxpokwekkFN8ALlkOptSWWaca0BaNVXpkcYqmCcWHZAt2OuXH6Zx8XlgcXhnVUA20fJMs4oSynJY3Sm5O0rw5g5NG7g_Lf8pdDFPBRoH0bggf7J6FEDrjlXo645YBbjrij7X60Qez55cDLoB1ELsZ50J00rfs_4AfLP4mq
Cites_doi	10.1016/j.biochi.2024.10.004 10.18632/oncotarget.2460 10.1016/j.bioorg.2014.09.003 10.1371/journal.pone.0121725 10.1023/A:1011926116777 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J 10.1016/j.redox.2013.12.020 10.18632/oncotarget.13601 10.1096/fj.13-239285 10.1007/s10637-022-01258-y 10.1007/s10549-013-2743-3 10.1016/j.ejmech.2018.03.046 10.1158/1535-7163.MCT-18-1233 10.1074/mcp.M200008-MCP200 10.1210/er.2013-1053 10.1074/jbc.M113.457622 10.1002/elps.1150180333 10.1023/A:1006338232150 10.1111/j.1742-4658.2009.06926.x 10.1111/j.1476-5381.2011.01729.x 10.1002/jcp.25650 10.1016/j.bcp.2018.03.023 10.1158/1078-0432.CCR-0811-03 10.1007/s10911-017-9371-1 10.1007/BF01612908 10.2217/epi-2019-0207 10.1016/j.maturitas.2004.04.011 10.1007/s10549-015-3445-9 10.1186/bcr2889 10.1164/rccm.201301-0021PP 10.1038/nprot.2008.73 10.1093/carcin/9.4.653 10.1038/sj.onc.1210172 10.1089/biores.2012.0270 10.1016/j.coph.2011.10.003 10.1073/pnas.81.15.4950 10.1016/0006-2952(95)00108-C 10.1126/science.6269181 10.1002/jcb.30325
ContentType	Journal Article
Copyright	2025 Elsevier B.V. Copyright © 2025 Elsevier B.V. All rights reserved. Copyright © 2025. Published by Elsevier B.V.
Copyright_xml	– notice: 2025 Elsevier B.V. – notice: Copyright © 2025 Elsevier B.V. All rights reserved. – notice: Copyright © 2025. Published by Elsevier B.V.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.bbagen.2025.130850
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Chemistry Biology
EISSN	1872-8006
ExternalDocumentID	40816541 10_1016_j_bbagen_2025_130850 S0304416525000959
Genre	Journal Article
GroupedDBID	--- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABEFU ABFNM ABGSF ABMAC ABUDA ABWVN ABXDB ACDAQ ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AEUPX AFJKZ AFPUW AFTJW AFXIZ AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CS3 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HLW HVGLF HZ~ IHE J1W KOM LX3 M41 MO0 N9A O-L O9- OAUVE OHT OZT P-8 P-9 PC. Q38 R2- ROL RPZ SBG SCC SDF SDG SDP SES SEW SPCBC SSU SSZ T5K UQL WH7 WUQ XJT XPP ~G- ~HD 9DU AAYXX CITATION AGCQF CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c346t-7e85df3f4101e7a1b43c05dc9154de4736e8ccf0f3c33cfedca6bd6e0307345f3
ISICitedReferencesCount	0
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001559923400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0304-4165 1872-8006
IngestDate	Thu Oct 02 21:47:59 EDT 2025 Fri Sep 19 01:51:10 EDT 2025 Sat Nov 29 07:25:31 EST 2025 Sun Oct 19 02:02:22 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	11
Keywords	Cyclic AMP Cell line Roflumilast Phosphodiesterase 4 inhibitor Gene expression Breast neoplasm
Language	English
License	Copyright © 2025 Elsevier B.V. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c346t-7e85df3f4101e7a1b43c05dc9154de4736e8ccf0f3c33cfedca6bd6e0307345f3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	40816541
PQID	3240136181
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_3240136181 pubmed_primary_40816541 crossref_primary_10_1016_j_bbagen_2025_130850 elsevier_sciencedirect_doi_10_1016_j_bbagen_2025_130850
PublicationCentury	2000
PublicationDate	2025-10-01
PublicationDateYYYYMMDD	2025-10-01
PublicationDate_xml	– month: 10 year: 2025 text: 2025-10-01 day: 01
PublicationDecade	2020
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	Biochimica et biophysica acta. General subjects
PublicationTitleAlternate	Biochim Biophys Acta Gen Subj
PublicationYear	2025
Publisher	Elsevier B.V
Publisher_xml	– name: Elsevier B.V
References	Baillie (bb0175) 2009; 276 Davari, Abnous, Mehri (bb0200) 2014; 57 Tice, Agurell, Anderson (bb0085) 2000; 35 Davio, Cricco, Bergoc, Rivera (bb0065) 1995; 50 Uranga, Katz, Salvador (bb0070) 2013; 288 Chen, Gharib, Huang (bb0160) 2002; 1 Gargiulo, May, Rivero (bb0035) 2017; 22 Gyori, Venkatachalam, Thiagarajan (bb0090) 2014; 2 Konrad, Bury, Schick (bb0230) 2015; 10 Spina, di Maiolo, Esposito (bb0020) 2012; 1 Sapio, Gallo, Illiano (bb0040) 2017; 232 Keravis, Lugnier (bb0095) 2012; 165 Edavana, Penney, Yao-Borengasser (bb0115) 2013; 2 Drees, Zimmermann, Eisenbrand (bb0105) 1993; 53 Cho-Chung, Clair, Bodwin, Berghoffer (bb0130) 1981; 214 Bagchi, Bhattacharya, Chatterji, Biswas (bb0185) 2024 Silberstein, Strickland, Trumpbour (bb0055) 1984; 81 Anderson, Seilhamer (bb0170) 1997; 18 Holliday, Speirs (bb0215) 2011; 13 Illiano, Sapio, Salzillo (bb0045) 2018; 152 Vandewalle, Revillion, Lefebvre (bb0050) 1990; 116 Fertig, Baillie (bb0180) 2018; 5 Prabahar, Zamora, Barclay (bb0165) 2024; 6 Principe, Lezcano, Tiburzi (bb0080) 2025; 229 Spychala, Lazarowski, Ostapkowicz (bb0120) 2004; 10 Gargiulo, Copsel, Rivero (bb0005) 2014; 5 Mukherjee, Bagchi, Banerjee (bb0110) 2022; 123 Prat, Karginova, Parker (bb0210) 2013; 142 Dong, Claffey, Brocke, Epstein (bb0025) 2015; 152 Murata, Sudo, Kameyama (bb0010) 2000; 18 Azevedo, Faucz, Bimpaki (bb0030) 2014; 35 Janjua, Fortescue, Poole (bb0220) 2020 Schmittgen, Livak (bb0075) 2008; 3 Carie, Sebti (bb0125) 2007; 26 Bruzzone, Saulière, Finana (bb0135) 2014; 28 Wang, Li, Zhu (bb0140) 2016; 7 Beghe, Rabe, Fabbri (bb0225) 2013; 188 Liang, Chen, Mao (bb0195) 2022; 40 Russo, Russo (bb0060) 2004; 49 Hao, Shen, Du (bb0205) 2020; 19 Levy, Horvath, Azevedo (bb0150) 2011; 11 Bagchi, Roy, Halder, Biswas (bb0190) 2024 Vanhamme, Szpirer (bb0100) 1988; 9 Fan, Mu, Huang (bb0145) 2019; 11 Slotkin, Zhang, Dancel (bb0015) 2000; 60 Peng, Gong, Jin (bb0155) 2018; 150 Anderson (10.1016/j.bbagen.2025.130850_bb0170) 1997; 18 Konrad (10.1016/j.bbagen.2025.130850_bb0230) 2015; 10 Cho-Chung (10.1016/j.bbagen.2025.130850_bb0130) 1981; 214 Dong (10.1016/j.bbagen.2025.130850_bb0025) 2015; 152 Prat (10.1016/j.bbagen.2025.130850_bb0210) 2013; 142 Russo (10.1016/j.bbagen.2025.130850_bb0060) 2004; 49 Liang (10.1016/j.bbagen.2025.130850_bb0195) 2022; 40 Davari (10.1016/j.bbagen.2025.130850_bb0200) 2014; 57 Levy (10.1016/j.bbagen.2025.130850_bb0150) 2011; 11 Chen (10.1016/j.bbagen.2025.130850_bb0160) 2002; 1 Bruzzone (10.1016/j.bbagen.2025.130850_bb0135) 2014; 28 Holliday (10.1016/j.bbagen.2025.130850_bb0215) 2011; 13 Slotkin (10.1016/j.bbagen.2025.130850_bb0015) 2000; 60 Drees (10.1016/j.bbagen.2025.130850_bb0105) 1993; 53 Hao (10.1016/j.bbagen.2025.130850_bb0205) 2020; 19 Murata (10.1016/j.bbagen.2025.130850_bb0010) 2000; 18 Wang (10.1016/j.bbagen.2025.130850_bb0140) 2016; 7 Edavana (10.1016/j.bbagen.2025.130850_bb0115) 2013; 2 Prabahar (10.1016/j.bbagen.2025.130850_bb0165) 2024; 6 Azevedo (10.1016/j.bbagen.2025.130850_bb0030) 2014; 35 Keravis (10.1016/j.bbagen.2025.130850_bb0095) 2012; 165 Mukherjee (10.1016/j.bbagen.2025.130850_bb0110) 2022; 123 Fertig (10.1016/j.bbagen.2025.130850_bb0180) 2018; 5 Davio (10.1016/j.bbagen.2025.130850_bb0065) 1995; 50 Uranga (10.1016/j.bbagen.2025.130850_bb0070) 2013; 288 Baillie (10.1016/j.bbagen.2025.130850_bb0175) 2009; 276 Sapio (10.1016/j.bbagen.2025.130850_bb0040) 2017; 232 Vandewalle (10.1016/j.bbagen.2025.130850_bb0050) 1990; 116 Schmittgen (10.1016/j.bbagen.2025.130850_bb0075) 2008; 3 Gyori (10.1016/j.bbagen.2025.130850_bb0090) 2014; 2 Carie (10.1016/j.bbagen.2025.130850_bb0125) 2007; 26 Fan (10.1016/j.bbagen.2025.130850_bb0145) 2019; 11 Bagchi (10.1016/j.bbagen.2025.130850_bb0185) 2024 Beghe (10.1016/j.bbagen.2025.130850_bb0225) 2013; 188 Principe (10.1016/j.bbagen.2025.130850_bb0080) 2025; 229 Gargiulo (10.1016/j.bbagen.2025.130850_bb0035) 2017; 22 Tice (10.1016/j.bbagen.2025.130850_bb0085) 2000; 35 Bagchi (10.1016/j.bbagen.2025.130850_bb0190) 2024 Gargiulo (10.1016/j.bbagen.2025.130850_bb0005) 2014; 5 Spychala (10.1016/j.bbagen.2025.130850_bb0120) 2004; 10 Janjua (10.1016/j.bbagen.2025.130850_bb0220) 2020 Illiano (10.1016/j.bbagen.2025.130850_bb0045) 2018; 152 Spina (10.1016/j.bbagen.2025.130850_bb0020) 2012; 1 Vanhamme (10.1016/j.bbagen.2025.130850_bb0100) 1988; 9 Silberstein (10.1016/j.bbagen.2025.130850_bb0055) 1984; 81 Peng (10.1016/j.bbagen.2025.130850_bb0155) 2018; 150
References_xml	– volume: 26 start-page: 3777 year: 2007 end-page: 3788 ident: bb0125 article-title: A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway publication-title: Oncogene – volume: 19 start-page: 868 year: 2020 end-page: 881 ident: bb0205 article-title: Phosphodiesterase 3A represents a therapeutic target that drives stem cell-like property and metastasis in breast Cancer publication-title: Mol. Cancer Ther. – volume: 232 start-page: 922 year: 2017 end-page: 927 ident: bb0040 article-title: The natural cAMP elevating compound Forskolin in Cancer therapy: is it time? publication-title: J. Cell. Physiol. – volume: 49 start-page: 2 year: 2004 end-page: 15 ident: bb0060 article-title: Development of the human breast publication-title: Maturitas – year: 2024 ident: bb0185 article-title: PDE4 Inhibitor Rolipram Represses Hedgehog Signaling Via Ubiquitin-mediated Proteolysis of GLI Transcription Factors to Regress Breast Cancer – volume: 60 start-page: 153 year: 2000 end-page: 166 ident: bb0015 article-title: Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells publication-title: Breast Cancer Res. Treat. – volume: 6 year: 2024 ident: bb0165 article-title: Unraveling the complex relationship between mRNA and protein abundances: a machine learning-based approach for imputing protein levels from RNA-seq data publication-title: NAR Genom. Bioinform. – volume: 5 year: 2018 ident: bb0180 article-title: PDE4-mediated cAMP signalling publication-title: J. Cardiovasc. Dev. Dis. – volume: 142 start-page: 237 year: 2013 end-page: 255 ident: bb0210 article-title: Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes publication-title: Breast Cancer Res. Treat. – volume: 9 start-page: 653 year: 1988 end-page: 655 ident: bb0100 article-title: Transforming activity of the human mammary line HBL100 DNA is associated with SV40 large T antigen genetic information integrated in its genome publication-title: Carcinogenesis – volume: 123 year: 2022 ident: bb0110 article-title: PDE4 inhibitor eliminates breast cancer stem cells via noncanonical activation of mTOR publication-title: J. Cell. Biochem. – volume: 1 start-page: 324 year: 2012 end-page: 332 ident: bb0020 article-title: cAMP elevation Down-regulates β3 integrin and focal adhesion kinase and inhibits leptin-induced migration of MDA-MB-231 breast Cancer cells publication-title: Biores Open Access – volume: 152 start-page: 104 year: 2018 end-page: 113 ident: bb0045 article-title: Forskolin improves sensitivity to doxorubicin of triple negative breast cancer cells via protein kinase A-mediated ERK1/2 inhibition publication-title: Biochem. Pharmacol. – volume: 188 start-page: 271 year: 2013 end-page: 278 ident: bb0225 article-title: Phosphodiesterase-4 inhibitor therapy for lung diseases publication-title: Am. J. Respir. Crit. Care Med. – volume: 50 start-page: 91 year: 1995 end-page: 96 ident: bb0065 article-title: H1 and H2 histamine receptors in n-nitroso-N-methylurea (NMU)-induced carcinomas with atypical coupling to signal transducers publication-title: Biochem. Pharmacol. – volume: 3 start-page: 1101 year: 2008 end-page: 1108 ident: bb0075 article-title: Analyzing real-time PCR data by the comparative CT method publication-title: Nat. Protoc. – volume: 276 start-page: 1790 year: 2009 end-page: 1799 ident: bb0175 article-title: Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases publication-title: FEBS J. – volume: 5 start-page: 10058 year: 2014 end-page: 10069 ident: bb0005 article-title: Differential β₂-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines publication-title: Oncotarget – volume: 22 start-page: 43 year: 2017 end-page: 57 ident: bb0035 article-title: A novel effect of β-adrenergic receptor on mammary branching morphogenesis and its possible implications in breast Cancer publication-title: J. Mammary Gland Biol. Neoplasia – volume: 10 start-page: 708 year: 2004 end-page: 717 ident: bb0120 article-title: Role of estrogen receptor in the regulation of ecto-5′-nucleotidase and adenosine in breast cancer publication-title: Clin. Cancer Res. – volume: 35 start-page: 195 year: 2014 end-page: 233 ident: bb0030 article-title: Clinical and molecular genetics of the phosphodiesterases (PDEs) publication-title: Endocr. Rev. – volume: 35 start-page: 206 year: 2000 end-page: 221 ident: bb0085 article-title: Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing publication-title: Environ. Mol. Mutagen. – volume: 57 start-page: 83 year: 2014 end-page: 89 ident: bb0200 article-title: Synthesis and biological evaluation of novel pyridine derivatives as potential anticancer agents and phosphodiesterase-3 inhibitors publication-title: Bioorg. Chem. – volume: 13 year: 2011 ident: bb0215 article-title: Choosing the right cell line for breast cancer research publication-title: Breast Cancer Res. – year: 2020 ident: bb0220 article-title: Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease publication-title: Cochrane Database Syst. Rev. – volume: 2 start-page: 1 year: 2013 end-page: 9 ident: bb0115 article-title: Fulvestrant Up Regulates UGT1A4 and MRPs Through ERα and c-Myb Pathways: A Possible Primary Drug Disposition Mechanism – volume: 10 year: 2015 ident: bb0230 article-title: The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation publication-title: PloS One – volume: 229 start-page: 30 year: 2025 end-page: 41 ident: bb0080 article-title: In vitro and in vivo evidence of the antineoplastic activity of quercetin against endothelial cells transformed by Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor publication-title: Biochimie – volume: 40 start-page: 875 year: 2022 end-page: 883 ident: bb0195 article-title: ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer publication-title: Invest. New Drugs – volume: 2 start-page: 457 year: 2014 end-page: 465 ident: bb0090 article-title: OpenComet: an automated tool for comet assay image analysis publication-title: Redox Biol. – volume: 11 start-page: 689 year: 2011 end-page: 697 ident: bb0150 article-title: Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment publication-title: Curr. Opin. Pharmacol. – volume: 116 start-page: 303 year: 1990 end-page: 306 ident: bb0050 article-title: Functional β-adrenergic receptors in breast cancer cells publication-title: J. Cancer Res. Clin. Oncol. – volume: 7 start-page: 87232 year: 2016 end-page: 87245 ident: bb0140 article-title: Triple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition publication-title: Oncotarget – volume: 53 start-page: 3058 year: 1993 end-page: 3061 ident: bb0105 article-title: 3′,5′-cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition publication-title: Cancer Res. – volume: 150 start-page: 742 year: 2018 end-page: 756 ident: bb0155 article-title: Inhibitors of phosphodiesterase as cancer therapeutics publication-title: Eur. J. Med. Chem. – volume: 1 start-page: 304 year: 2002 end-page: 313 ident: bb0160 article-title: Discordant protein and mRNA expression in lung adenocarcinomas publication-title: Mol. Cell. Proteomics – volume: 288 start-page: 19773 year: 2013 end-page: 19784 ident: bb0070 article-title: Enhanced phosphatidylinositol 3-kinase (PI3K)/Akt signaling has pleiotropic targets in hippocampal neurons exposed to iron-induced oxidative stress publication-title: J. Biol. Chem. – volume: 18 start-page: 599 year: 2000 end-page: 604 ident: bb0010 article-title: Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility publication-title: Clin. Exp. Metastasis – volume: 165 start-page: 1288 year: 2012 end-page: 1305 ident: bb0095 article-title: Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments publication-title: Br. J. Pharmacol. – volume: 11 start-page: 1561 year: 2019 end-page: 1579 ident: bb0145 article-title: Epigenetic identification of ADCY4 as a biomarker for breast cancer: an integrated analysis of adenylate cyclases publication-title: Epigenomics – volume: 81 start-page: 4950 year: 1984 end-page: 4954 ident: bb0055 article-title: In vivo, cAMP stimulates growth and morphogenesis of mouse mammary ducts publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 152 start-page: 17 year: 2015 end-page: 28 ident: bb0025 article-title: Inhibition of breast cancer cell migration by activation of cAMP signaling publication-title: Breast Cancer Res. Treat. – year: 2024 ident: bb0190 article-title: The Hidden Potential of PDE4 Inhibitor Rolipram: A Multifaceted Examination of Its Inhibition of MMP2/9 Reveals Therapeutic Implications – volume: 28 start-page: 1342 year: 2014 end-page: 1354 ident: bb0135 article-title: Dosage-dependent regulation of cell proliferation and adhesion through dual β2-adrenergic receptor/cAMP signals publication-title: FASEB J. – volume: 18 start-page: 533 year: 1997 end-page: 537 ident: bb0170 article-title: A comparison of selected mRNA and protein abundances in human liver publication-title: Electrophoresis – volume: 214 start-page: 77 year: 1981 end-page: 79 ident: bb0130 article-title: Growth arrest and morphological change of human breast cancer cells by dibutyryl cyclic AMP and L-arginine publication-title: Science – volume: 229 start-page: 30 year: 2025 ident: 10.1016/j.bbagen.2025.130850_bb0080 article-title: In vitro and in vivo evidence of the antineoplastic activity of quercetin against endothelial cells transformed by Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor publication-title: Biochimie doi: 10.1016/j.biochi.2024.10.004 – volume: 2 start-page: 1 year: 2013 ident: 10.1016/j.bbagen.2025.130850_bb0115 – volume: 53 start-page: 3058 year: 1993 ident: 10.1016/j.bbagen.2025.130850_bb0105 article-title: 3′,5′-cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition publication-title: Cancer Res. – volume: 5 start-page: 10058 year: 2014 ident: 10.1016/j.bbagen.2025.130850_bb0005 article-title: Differential β₂-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines publication-title: Oncotarget doi: 10.18632/oncotarget.2460 – volume: 57 start-page: 83 year: 2014 ident: 10.1016/j.bbagen.2025.130850_bb0200 article-title: Synthesis and biological evaluation of novel pyridine derivatives as potential anticancer agents and phosphodiesterase-3 inhibitors publication-title: Bioorg. Chem. doi: 10.1016/j.bioorg.2014.09.003 – volume: 10 year: 2015 ident: 10.1016/j.bbagen.2025.130850_bb0230 article-title: The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation publication-title: PloS One doi: 10.1371/journal.pone.0121725 – volume: 18 start-page: 599 year: 2000 ident: 10.1016/j.bbagen.2025.130850_bb0010 article-title: Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility publication-title: Clin. Exp. Metastasis doi: 10.1023/A:1011926116777 – volume: 35 start-page: 206 year: 2000 ident: 10.1016/j.bbagen.2025.130850_bb0085 article-title: Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing publication-title: Environ. Mol. Mutagen. doi: 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J – volume: 2 start-page: 457 year: 2014 ident: 10.1016/j.bbagen.2025.130850_bb0090 article-title: OpenComet: an automated tool for comet assay image analysis publication-title: Redox Biol. doi: 10.1016/j.redox.2013.12.020 – volume: 7 start-page: 87232 year: 2016 ident: 10.1016/j.bbagen.2025.130850_bb0140 article-title: Triple negative breast cancer development can be selectively suppressed by sustaining an elevated level of cellular cyclic AMP through simultaneously blocking its efflux and decomposition publication-title: Oncotarget doi: 10.18632/oncotarget.13601 – volume: 28 start-page: 1342 year: 2014 ident: 10.1016/j.bbagen.2025.130850_bb0135 article-title: Dosage-dependent regulation of cell proliferation and adhesion through dual β2-adrenergic receptor/cAMP signals publication-title: FASEB J. doi: 10.1096/fj.13-239285 – volume: 40 start-page: 875 year: 2022 ident: 10.1016/j.bbagen.2025.130850_bb0195 article-title: ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer publication-title: Invest. New Drugs doi: 10.1007/s10637-022-01258-y – volume: 142 start-page: 237 year: 2013 ident: 10.1016/j.bbagen.2025.130850_bb0210 article-title: Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-013-2743-3 – volume: 150 start-page: 742 year: 2018 ident: 10.1016/j.bbagen.2025.130850_bb0155 article-title: Inhibitors of phosphodiesterase as cancer therapeutics publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2018.03.046 – volume: 19 start-page: 868 year: 2020 ident: 10.1016/j.bbagen.2025.130850_bb0205 article-title: Phosphodiesterase 3A represents a therapeutic target that drives stem cell-like property and metastasis in breast Cancer publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-18-1233 – volume: 1 start-page: 304 year: 2002 ident: 10.1016/j.bbagen.2025.130850_bb0160 article-title: Discordant protein and mRNA expression in lung adenocarcinomas publication-title: Mol. Cell. Proteomics doi: 10.1074/mcp.M200008-MCP200 – volume: 35 start-page: 195 year: 2014 ident: 10.1016/j.bbagen.2025.130850_bb0030 article-title: Clinical and molecular genetics of the phosphodiesterases (PDEs) publication-title: Endocr. Rev. doi: 10.1210/er.2013-1053 – volume: 288 start-page: 19773 year: 2013 ident: 10.1016/j.bbagen.2025.130850_bb0070 article-title: Enhanced phosphatidylinositol 3-kinase (PI3K)/Akt signaling has pleiotropic targets in hippocampal neurons exposed to iron-induced oxidative stress publication-title: J. Biol. Chem. doi: 10.1074/jbc.M113.457622 – volume: 5 year: 2018 ident: 10.1016/j.bbagen.2025.130850_bb0180 article-title: PDE4-mediated cAMP signalling publication-title: J. Cardiovasc. Dev. Dis. – volume: 18 start-page: 533 year: 1997 ident: 10.1016/j.bbagen.2025.130850_bb0170 article-title: A comparison of selected mRNA and protein abundances in human liver publication-title: Electrophoresis doi: 10.1002/elps.1150180333 – year: 2020 ident: 10.1016/j.bbagen.2025.130850_bb0220 article-title: Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease publication-title: Cochrane Database Syst. Rev. – volume: 60 start-page: 153 year: 2000 ident: 10.1016/j.bbagen.2025.130850_bb0015 article-title: Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells publication-title: Breast Cancer Res. Treat. doi: 10.1023/A:1006338232150 – volume: 276 start-page: 1790 year: 2009 ident: 10.1016/j.bbagen.2025.130850_bb0175 article-title: Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases publication-title: FEBS J. doi: 10.1111/j.1742-4658.2009.06926.x – volume: 165 start-page: 1288 year: 2012 ident: 10.1016/j.bbagen.2025.130850_bb0095 article-title: Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.2011.01729.x – volume: 232 start-page: 922 year: 2017 ident: 10.1016/j.bbagen.2025.130850_bb0040 article-title: The natural cAMP elevating compound Forskolin in Cancer therapy: is it time? publication-title: J. Cell. Physiol. doi: 10.1002/jcp.25650 – volume: 152 start-page: 104 year: 2018 ident: 10.1016/j.bbagen.2025.130850_bb0045 article-title: Forskolin improves sensitivity to doxorubicin of triple negative breast cancer cells via protein kinase A-mediated ERK1/2 inhibition publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2018.03.023 – volume: 10 start-page: 708 year: 2004 ident: 10.1016/j.bbagen.2025.130850_bb0120 article-title: Role of estrogen receptor in the regulation of ecto-5′-nucleotidase and adenosine in breast cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-0811-03 – year: 2024 ident: 10.1016/j.bbagen.2025.130850_bb0190 – volume: 22 start-page: 43 year: 2017 ident: 10.1016/j.bbagen.2025.130850_bb0035 article-title: A novel effect of β-adrenergic receptor on mammary branching morphogenesis and its possible implications in breast Cancer publication-title: J. Mammary Gland Biol. Neoplasia doi: 10.1007/s10911-017-9371-1 – volume: 116 start-page: 303 year: 1990 ident: 10.1016/j.bbagen.2025.130850_bb0050 article-title: Functional β-adrenergic receptors in breast cancer cells publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/BF01612908 – volume: 11 start-page: 1561 year: 2019 ident: 10.1016/j.bbagen.2025.130850_bb0145 article-title: Epigenetic identification of ADCY4 as a biomarker for breast cancer: an integrated analysis of adenylate cyclases publication-title: Epigenomics doi: 10.2217/epi-2019-0207 – volume: 49 start-page: 2 year: 2004 ident: 10.1016/j.bbagen.2025.130850_bb0060 article-title: Development of the human breast publication-title: Maturitas doi: 10.1016/j.maturitas.2004.04.011 – volume: 152 start-page: 17 year: 2015 ident: 10.1016/j.bbagen.2025.130850_bb0025 article-title: Inhibition of breast cancer cell migration by activation of cAMP signaling publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-015-3445-9 – volume: 13 year: 2011 ident: 10.1016/j.bbagen.2025.130850_bb0215 article-title: Choosing the right cell line for breast cancer research publication-title: Breast Cancer Res. doi: 10.1186/bcr2889 – volume: 188 start-page: 271 year: 2013 ident: 10.1016/j.bbagen.2025.130850_bb0225 article-title: Phosphodiesterase-4 inhibitor therapy for lung diseases publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/rccm.201301-0021PP – volume: 3 start-page: 1101 year: 2008 ident: 10.1016/j.bbagen.2025.130850_bb0075 article-title: Analyzing real-time PCR data by the comparative CT method publication-title: Nat. Protoc. doi: 10.1038/nprot.2008.73 – volume: 9 start-page: 653 year: 1988 ident: 10.1016/j.bbagen.2025.130850_bb0100 article-title: Transforming activity of the human mammary line HBL100 DNA is associated with SV40 large T antigen genetic information integrated in its genome publication-title: Carcinogenesis doi: 10.1093/carcin/9.4.653 – volume: 26 start-page: 3777 year: 2007 ident: 10.1016/j.bbagen.2025.130850_bb0125 article-title: A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway publication-title: Oncogene doi: 10.1038/sj.onc.1210172 – year: 2024 ident: 10.1016/j.bbagen.2025.130850_bb0185 – volume: 1 start-page: 324 year: 2012 ident: 10.1016/j.bbagen.2025.130850_bb0020 article-title: cAMP elevation Down-regulates β3 integrin and focal adhesion kinase and inhibits leptin-induced migration of MDA-MB-231 breast Cancer cells publication-title: Biores Open Access doi: 10.1089/biores.2012.0270 – volume: 11 start-page: 689 year: 2011 ident: 10.1016/j.bbagen.2025.130850_bb0150 article-title: Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2011.10.003 – volume: 81 start-page: 4950 year: 1984 ident: 10.1016/j.bbagen.2025.130850_bb0055 article-title: In vivo, cAMP stimulates growth and morphogenesis of mouse mammary ducts publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.81.15.4950 – volume: 6 year: 2024 ident: 10.1016/j.bbagen.2025.130850_bb0165 article-title: Unraveling the complex relationship between mRNA and protein abundances: a machine learning-based approach for imputing protein levels from RNA-seq data publication-title: NAR Genom. Bioinform. – volume: 50 start-page: 91 year: 1995 ident: 10.1016/j.bbagen.2025.130850_bb0065 article-title: H1 and H2 histamine receptors in n-nitroso-N-methylurea (NMU)-induced carcinomas with atypical coupling to signal transducers publication-title: Biochem. Pharmacol. doi: 10.1016/0006-2952(95)00108-C – volume: 214 start-page: 77 year: 1981 ident: 10.1016/j.bbagen.2025.130850_bb0130 article-title: Growth arrest and morphological change of human breast cancer cells by dibutyryl cyclic AMP and L-arginine publication-title: Science doi: 10.1126/science.6269181 – volume: 123 year: 2022 ident: 10.1016/j.bbagen.2025.130850_bb0110 article-title: PDE4 inhibitor eliminates breast cancer stem cells via noncanonical activation of mTOR publication-title: J. Cell. Biochem. doi: 10.1002/jcb.30325
SSID	ssj0000595
Score	2.4734557
Snippet	cAMP regulates key processes in mammary cell biology. Previous studies suggested reduced cAMP production in more malignant cells. This study investigates the...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Publisher
StartPage	130850
SubjectTerms	1-Methyl-3-isobutylxanthine - pharmacology Aminopyridines - pharmacology Benzamides - pharmacology Breast neoplasm Breast Neoplasms - drug therapy Breast Neoplasms - enzymology Breast Neoplasms - metabolism Breast Neoplasms - pathology Cell line Cell Line, Tumor Cell Movement - drug effects Cell Proliferation - drug effects Cell Survival - drug effects Cyclic AMP Cyclic AMP - metabolism Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism Cyclic Nucleotide Phosphodiesterases, Type 7 - antagonists & inhibitors Cyclic Nucleotide Phosphodiesterases, Type 7 - metabolism Cyclopropanes - pharmacology Female Gene expression Gene Expression Regulation, Neoplastic - drug effects Humans MCF-7 Cells Phosphodiesterase 4 inhibitor Phosphodiesterase 4 Inhibitors - pharmacology Phosphodiesterase Inhibitors - pharmacology Roflumilast
Title	Inhibition of phosphodiesterase 4 and 7 regulates breast cancer cell proliferation
URI	https://dx.doi.org/10.1016/j.bbagen.2025.130850 https://www.ncbi.nlm.nih.gov/pubmed/40816541 https://www.proquest.com/docview/3240136181
Volume	1869
WOSCitedRecordID	wos001559923400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1872-8006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000595 issn: 0304-4165 databaseCode: AIEXJ dateStart: 19950118 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6DgQvCMZX-ZiMxFuUqUmcr8dRBgzBNMGY-hbZjkMzlaRK2mnbf8N_yp0dpxpj4kPiIVFlN3V693N8Of_ujpCXsGSPfYlZPqMidlnMPZcLmbgRLO5jT7AkCKQuNhEfHCTTaXo4GHy3sTCn87iqkrOzdPFfVQ1toGwMnf0Ldfc_Cg3wGZQOZ1A7nP9I8fvVrBSlNQQXs7qFA7mCGGvcKofp_YLYaUwVetU6AonpS-R_SdU46MpH2tYcSS9rvdmN37KWsxJzDDhq6YiyNq4Rjkk5-I7NYu20K4EOnt5g_8jPAWu6dpihBUyQZmt7j9Gbn2MklIYP_8abvu8tb76WK7NB9GEl9cb-63VvXV3oJm-uLtxDgLv-4rFhALwKKktF6hwbfthT5Dpv25WIGxPlNWYuGJHh5Se4Kfdiser9cm0wboqTHSHgSY2pb_0Qa2EnJvHtT1m3P-NAOI6vK0aE6QbZ9OMwTYZkc3d_b_p-vdyHurRPf2M2PlOTCK-OdZ39c937jbZzju6SO90LCt01wLpHBqraIjdNydLzLXJrYisE3ief1lCjdUGvQI0yClCjMe2hRg3UqIEaRajRS1B7QL682TuavHO7Gh2uDFi0dGOVhHkRFAz-sIKZLlggx2EuUzDNc8XiIFKJlMW4CCTM-kLlkkcij5ReW1hYBA_JsKor9ZjQMOc-HF4CKy6DK4VfpLmnkjQXokiZHBHXSi5bmFQsmeUonmRG0hlKOjOSHpHYijfrzEljJmaAiN9c-cJqIwORojB4pepVm2H6Si-IwCwekUdGTf29MKxhEzLvyT-P-5TcXk-EZ2S4bFbqObkhT5dl22yTjXiabHfw-wGuiLDm
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibition+of+phosphodiesterase+4+and+7+regulates+breast+cancer+cell+proliferation&rft.jtitle=Biochimica+et+biophysica+acta.+General+subjects&rft.au=Mayora+Justel%2C+Carla&rft.au=Valladares%2C+Tamara&rft.au=Gargiulo%2C+Luc%C3%ADa&rft.au=Gonz%C3%A1lez-Pardo%2C+Ver%C3%B3nica&rft.date=2025-10-01&rft.pub=Elsevier+B.V&rft.issn=0304-4165&rft.volume=1869&rft.issue=11&rft_id=info:doi/10.1016%2Fj.bbagen.2025.130850&rft.externalDocID=S0304416525000959
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0304-4165&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0304-4165&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0304-4165&client=summon